A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
Clinical trial NCT06102928 · RECRUITING
Trial details
- NCT number
- NCT06102928
- Sponsor
- Kunming Medical University
- Status
- RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-30
- Primary completion
- 2026-10-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.